Comparison of Levothyroxine Formulation in Hypothyroid Patients With Enteral Feeding


The purpose of this study is to test a liquid levothyroxine formula and examine if it will lead to improvement in management of thyroid function and if it improves hypothyroid symptoms that patients experience.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: April 2022

Detailed Description

Patients who require enteral nutrition through an enteral feeding tube and have hypothyroidism often struggle with the management of hypothyroidism. Hypothyroidism usually requires lifelong treatment except in some cases. It has been clinically observed the traditional management of hypothyroidism is to crush the tablet and administer the medical through the enteral nutrition tube and hold the feeds for one hour. However, management of the hormonal profile has been noted to have variable results with this method. Limited data is available about the effectiveness of levothyroxine liquid formulation in outpatients' dependent on enteral feeding tubes for administration. Therefore, we propose a study to assess if daily treatment of, Tirosint-SOL (liquid levothyroxine, IBSA pharma Inc.), will improve thyroid function tests in individuals requiring enteral nutrition and are hypothyroid in a prospective, randomized study in a population requiring enteral nutrition. We hypothesize that Tirosint-SOL will lead to improvement in management in their thyroid function tests resulting in possible improvement in hypothyroid symptoms experienced by the patients. This will be a randomized controlled trial. The study will be conducted in patients who have uncontrolled hypothyroidism on levothyroxine therapy. These patients will also be dependent on enteral nutrition and medication administration through the gastrostomy tube. The participants will be followed at UCLA Enteral Nutrition Clinic. Participants will be randomized 1:1 to either continue current management with the same dose or to dose equivalent liquid levothyroxine. At baseline (week 0) and week 6-8, TSH and thyroid function tests will be performed. In addition, medical history and physical, body weight, HR, blood pressure, nutritional intake by a registered dietitian will be done at each visit.


  • Drug: Levothyroxine Tablet
    • Standard clinical management
  • Drug: Levothyroxine Sodium
    • Liquid levothyroxine through enteral feeding tube

Arms, Groups and Cohorts

  • Active Comparator: Standard Levothyroxine Management
    • Participants will continue with the same regimen
  • Experimental: Liquid Levothyroxine Management
    • Participants will be treated with dose equivalent regimen through enteral feeding tube

Clinical Trial Outcome Measures

Primary Measures

  • Change of TSH
    • Time Frame: 6 weeks
    • evaluate change in thyroid hormonal panel

Secondary Measures

  • percentage of patients with therapeutic FT4
    • Time Frame: 6 weeks
    • evaluate change in thyroid hormonal panel
  • percentage of patients with therapeutic FT3
    • Time Frame: 6 weeks
    • evaluate change in thyroid hormonal panel

Participating in This Clinical Trial

Inclusion Criteria

  • Adults age 18 years old or older – G-tube/G-J tube dependent for medication administration – Hypothyroid patients on levothyroxine tablet – TSH>5 on levothyroxine Exclusion Criteria:

  • J-tube – Unstable cardiac condition – Unstable gastrointestinal condition – Unable to reliably administer medication – Screening laboratory value outside of the laboratory normal range that is considered clinically significant for study participation by the investigator. – In the opinion of the study investigator, any subject who demonstrate a risk of non-compliance with study procedure, or one who cannot read, understand or complete study – related materials.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of California, Los Angeles
  • Provider of Information About this Clinical Study
    • Principal Investigator: Vijaya Surampudi MD, Principal Investigator – University of California, Los Angeles
  • Overall Official(s)
    • Vijiya Surampudi, MD, Principal Investigator, University of California, Los Angeles
  • Overall Contact(s)
    • Vijiya D Surampudi, MD, 310-206-1987,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.